Bartlett & CO. Wealth Management LLC lessened its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,277 shares of the financial services provider’s stock after selling 237 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in iShares Biotechnology ETF were worth $1,351,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of IBB. Future Financial Wealth Managment LLC purchased a new stake in shares of iShares Biotechnology ETF in the first quarter valued at approximately $27,000. Bbjs Financial Advisors LLC acquired a new stake in shares of iShares Biotechnology ETF in the 2nd quarter worth $31,000. Pacifica Partners Inc. increased its stake in shares of iShares Biotechnology ETF by 118.2% in the 1st quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after acquiring an additional 130 shares during the last quarter. Mather Group LLC. purchased a new position in shares of iShares Biotechnology ETF during the 1st quarter worth $57,000. Finally, Chris Bulman Inc acquired a new position in shares of iShares Biotechnology ETF during the 2nd quarter valued at about $64,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
iShares Biotechnology ETF stock opened at $145.91 on Friday. The company has a 50-day moving average price of $145.65 and a 200 day moving average price of $139.69. iShares Biotechnology ETF has a 12-month low of $111.83 and a 12-month high of $150.57.
iShares Biotechnology ETF Dividend Announcement
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- The 3 Best Blue-Chip Stocks to Buy Now
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 10/14 – 10/18
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.